Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. February 4, 20240CommentsRead More
SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation: Molecular Cell February 4, 20240CommentsRead More
SMURF-Therapeutics, Inc. Announces Six New Appointments to Scientific Advisory Board February 2, 20240CommentsRead More
FDA approves belzutifan for cancers associated with von Hippel-Lindau disease | FDA January 29, 20240CommentsRead MoreRead More
Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase | Oncotarget January 29, 20240CommentsRead MoreRead More
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease | NEJM January 29, 20240CommentsRead MoreRead More
Dr. Wafik El-Deiry comments on the future of cancer treatment January 17, 20240CommentsWatch NowRead More
Dr. Emile Youssef appointed Chief Medical Officer at SMURF-Therapeutics, Inc. December 28, 20230CommentsRead More